Thyroxine Treatment in Premature Infants With Intraventricular Hemorrhage
Public ClinicalTrials.gov record NCT03390530. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Thyroxine Treatment in Premature Infants With Intraventricular Hemorrhage: Phase III Clinical Trial
Study identification
- NCT ID
- NCT03390530
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- Thyroxine Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 3 Days to 6 Days
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 17, 2022
- Primary completion
- Dec 17, 2025
- Completion
- Jan 17, 2027
- Last update posted
- Jul 7, 2022
2022 – 2027
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Praveen Ballabh | The Bronx | New York | 10461 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03390530, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 7, 2022 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03390530 live on ClinicalTrials.gov.